Journal Article
PLXDC2 enhances invadopodium formation to promote invasion and metastasis of gastric cancer cells via interacting with PTP1B
Bin Wu; Yan-xia Wang; Jun-jie Wang; Dong-fang Xiang; Meng-si Zhang; Ze-xuan Yan; Wen-ying Wang; Jing-ya Miao; Xi Lan; Jia-jia Liu; Zheng-yan Li; Chuan Li; Jun-yan Fan; Jun-yan Liu; Lei Jiang; Sen-lin Xu; You-hong Cui; Feng Qian
Clinical & Experimental Metastasis · Vol. 39, Issue 4 · pp. 691-710 · 2022
Abstract
Plexin-domain containing 2 (PLXDC2) has been reported as an oncoprotein in several human malignancies. However, its expression and roles in gastric cancer remain largely unclear. In this study, we found that PLXDC2 was highly expressed in gastric cancer tissues, and the expression levels were positively correlated with clinicopathological features, but negatively with the patients’ outcome. Cox regression analysis identified PLXDC2 as an independent prognostic indicator for the patients. Knockdown of PLXDC2 markedly suppressed the in vitro invasion and in vivo metastasis of gastric cancer cells, while overexpression of PLXDC2 resulted in opposite effects. Mechanistically, PLXDC2 enhanced the level of phosphorylated Cortactin (p-Cortactin) by physically interacting with protein tyrosine phosphatase 1B (PTP1B), an important dephosphorylase, to prevent its dephosphorylating of p-Cortactin, thereby promoting the formation of invadopodia. Collectively, our results indicate that PLXDC2 contributes to the invasion and metastasis of gastric cancer by inhibiting PTP1B to facilitate the invadopodium formation, and may serve as a potential prognostic biomarker and a therapeutic target for this disease.